HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan).

Abstract
Thirteen patients with stage III or IV carcinoma of the prostate were treated with 2,6-cis-Diphenylhexamethylcyclotetrasiloxane (Cisobitan, a new organosilicon compound. The drug proved to be a strong antiandrogen and exerted all the known effects of estrogens, including feminization and cardiovascular complications. It is therefore doubtful whether Cisobitan will be a reasonable alternative to estrogens in the treatment of patients with advanced prostatic cancer.
AuthorsT Krarup, F Rasmussen, P A Gammelgaard
JournalScandinavian journal of urology and nephrology (Scand J Urol Nephrol) Vol. 12 Issue 1 Pg. 11-5 ( 1978) ISSN: 0036-5599 [Print] England
PMID345431 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Androgen Antagonists
  • Silicones
  • Siloxanes
Topics
  • Aged
  • Androgen Antagonists (administration & dosage, adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Drug Evaluation
  • Humans
  • Male
  • Prostatic Neoplasms (drug therapy)
  • Silicones (therapeutic use)
  • Siloxanes (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: